{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["enzalutamide"]],"indication":"metastatic castration-resistant prostate cancer","name":"NCT01942837","nct_id":"NCT01942837","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01942837. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Administration: 160 mg orally once daily with a 28-day cycle. Treatment will be continued until evidence of symptomatic or radiographic progression or the participant is taken off the study for another reason.\n\nDosing: 160 mg orally taken once daily as four 40 mg capsules.","label":"Enzalutamide","type":"EXPERIMENTAL"}],"collaborators":["Medivation, Inc."],"completion_date":{"date":"2022-09-30","type":"ACTUAL"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":67,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Enzalutamide","otherNames":["Xtandi"],"type":"DRUG"}],"last_update":"2022-10-24","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Patients With Gene Alterations","timeFrame":"Tumor biopsies were performed at pre-study and progression. Progression occurred up to 41 months after initiation of enzalutamide."}],"references":[{"citation":"Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, Scher HI, Rathkopf D, Dehm SM, Choueiri TK, Halabi S, Armstrong AJ, Wyatt AW, Taplin ME, Zhao SG, Lang JM. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. J Clin Oncol. 2021 Sep 10;39(26):2926-2937. doi: 10.1200/JCO.21.00169. Epub 2021 Jul 1.","pmid":"34197212","type":"DERIVED"}],"start_date":{"date":"2013-09-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT01942837"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01942837"}